Logo image of TDOC

TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis

NYSE:TDOC - New York Stock Exchange, Inc. - US87918A1051 - Common Stock - Currency: USD

6.86  -0.31 (-4.32%)

After market: 6.92 +0.06 (+0.87%)

Fundamental Rating

2

Overall TDOC gets a fundamental rating of 2 out of 10. We evaluated TDOC against 36 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. TDOC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TDOC had negative earnings in the past year.
TDOC had a positive operating cash flow in the past year.
In the past 5 years TDOC always reported negative net income.
Of the past 5 years TDOC 4 years had a positive operating cash flow.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5B -10B

1.2 Ratios

With a Return On Assets value of -29.39%, TDOC is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
TDOC has a worse Return On Equity (-70.94%) than 63.89% of its industry peers.
Industry RankSector Rank
ROA -29.39%
ROE -70.94%
ROIC N/A
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Gross Margin of TDOC (70.48%) is better than 75.00% of its industry peers.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

2

2. Health

2.1 Basic Checks

TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TDOC has more shares outstanding
TDOC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TDOC has a worse debt to assets ratio.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

TDOC has an Altman-Z score of -5.49. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a Altman-Z score of -5.49. This is amonst the worse of the industry: TDOC underperforms 80.56% of its industry peers.
TDOC has a debt to FCF ratio of 8.55. This is a slightly negative value and a sign of low solvency as TDOC would need 8.55 years to pay back of all of its debts.
With a Debt to FCF ratio value of 8.55, TDOC perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
TDOC has a Debt/Equity ratio of 0.70. This is a neutral value indicating TDOC is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.70, TDOC is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 8.55
Altman-Z -5.49
ROIC/WACCN/A
WACC7.24%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 1.68 indicates that TDOC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.68, TDOC is in line with its industry, outperforming 41.67% of the companies in the same industry.
TDOC has a Quick Ratio of 1.64. This is a normal value and indicates that TDOC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.64, TDOC perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.64
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.22% over the past year.
TDOC shows a decrease in Revenue. In the last year, the revenue decreased by -2.54%.
Measured over the past years, TDOC shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.
EPS 1Y (TTM)9.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.16%
Revenue 1Y (TTM)-2.54%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.59%

3.2 Future

TDOC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.67% yearly.
Based on estimates for the next years, TDOC will show a small growth in Revenue. The Revenue will grow by 2.10% on average per year.
EPS Next Y12.03%
EPS Next 2Y16.47%
EPS Next 3Y11.35%
EPS Next 5Y5.67%
Revenue Next Year-2.02%
Revenue Next 2Y-0.36%
Revenue Next 3Y0.43%
Revenue Next 5Y2.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TDOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TDOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TDOC indicates a rather cheap valuation: TDOC is cheaper than 97.22% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaper than 97.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.67
EV/EBITDA 8.78
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.47%
EPS Next 3Y11.35%

More info and screens

0

5. Dividend

5.1 Amount

TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELADOC HEALTH INC

NYSE:TDOC (6/13/2025, 8:04:00 PM)

After market: 6.92 +0.06 (+0.87%)

6.86

-0.31 (-4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners74.38%
Inst Owner Change-1.59%
Ins Owners0.5%
Ins Owner Change3.49%
Market Cap1.20B
Analysts68.13
Price Target9.05 (31.92%)
Short Float %12.44%
Short Ratio4.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.28%
Min EPS beat(2)-54.19%
Max EPS beat(2)-14.38%
EPS beat(4)2
Avg EPS beat(4)-3.81%
Min EPS beat(4)-54.19%
Max EPS beat(4)32.44%
EPS beat(8)5
Avg EPS beat(8)1.82%
EPS beat(12)7
Avg EPS beat(12)-998.7%
EPS beat(16)10
Avg EPS beat(16)-744.12%
Revenue beat(2)0
Avg Revenue beat(2)-1.08%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-0.35%
Revenue beat(4)0
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-3.05%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.74%
Revenue beat(12)0
Avg Revenue beat(12)-1.47%
Revenue beat(16)0
Avg Revenue beat(16)-1.45%
PT rev (1m)-3.71%
PT rev (3m)-17.23%
EPS NQ rev (1m)-3.42%
EPS NQ rev (3m)-9.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.4%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-1.48%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF 6.67
P/OCF 4
P/B 0.84
P/tB N/A
EV/EBITDA 8.78
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)1.03
FCFY15%
OCF(TTM)1.71
OCFY24.98%
SpS14.55
BVpS8.13
TBVpS-1.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.39%
ROE -70.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.48%
FCFM 7.07%
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score4
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 8.55
Debt/EBITDA 5.61
Cap/Depr 33.04%
Cap/Sales 4.71%
Interest Coverage N/A
Cash Conversion 170%
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.64
Altman-Z -5.49
F-Score4
WACC7.24%
ROIC/WACCN/A
Cap/Depr(3y)48.66%
Cap/Depr(5y)42.76%
Cap/Sales(3y)6.01%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.16%
EPS Next Y12.03%
EPS Next 2Y16.47%
EPS Next 3Y11.35%
EPS Next 5Y5.67%
Revenue 1Y (TTM)-2.54%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.59%
Revenue Next Year-2.02%
Revenue Next 2Y-0.36%
Revenue Next 3Y0.43%
Revenue Next 5Y2.1%
EBIT growth 1Y16.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.25%
EBIT Next 3Y35.51%
EBIT Next 5Y20.7%
FCF growth 1Y287.46%
FCF growth 3Y9.25%
FCF growth 5Y54.93%
OCF growth 1Y28.39%
OCF growth 3Y14.82%
OCF growth 5Y57.92%